Novartis: brolucizumab demonstrates solid visual gains.

(CercleFinance.com) - Novartis said on Tuesday that its drug RTH258 (brolucizumab) has demonstrated robust visual gains in patients with neovascular age-related macular degeneration.


The Swiss biopharmaceutical company's next generation anti-VEGF treatment was successful in reaching the primary endpoint in two phase III studies enrolling over 1,800 patients across 400 centers worldwide.

The primary efficacy endpoint was non-inferiority relative to Regeneron's aflibercept.

The trials showed that RTH258 was generally well tolerated, with overall ocular and non-ocular adverse event rates comparable to aflibercept.


Copyright (c) 2017 CercleFinance.com. All rights reserved.